Description of the medicine: Risperidone (Risperidone)

RISPERIDONE (Risperidone).

3- [2- [4- (6-Fluoro-1,2-benzoxazol-3-yl) piperidino] ethyl] 6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2- A] pyrimidin-1-one.

Synonyms: Rispolept, Rispolept, Risperdal.

A whitish-beige powder. Virtually nerastvorim in water, easily soluble in methanol and methylene chloride.

It is an selective blocker of 5-HT2-serotonin, D2-dopamine, A-adrenergic receptors and H1-histamine receptors.

Quickly and completely absorbed in the digestive tract, Cmax is 1-2 h, T1 / 2 risperidone and its active oxymetabolite - respectively 3 and 24 h; Is excreted mainly by the kidneys.

Applied in schizophrenia and other psychoses with a predominance of productive disorders (delirium, hallucinations) and negative symptoms, as well as with vegetative disorders in patients with schizophrenia.

Assign inside, starting with 0,001 g (1 mg) 2 times a day and daily increasing the dose by 0.001 g until the therapeutic effect. The average daily dose is 0.004-0.006 g (4-6 mg). Elderly patients and with renal and hepatic insufficiency appoint 0.0005g (0.5 mg) 2 times a day. The maximum daily dose of 0.004 g (4 mg).

With the use of risperidone, sleep disorders, increased excitability, extrapyramidal disorders, dyspepsia, arterial hypotension, tachycardia, galactorrhea, gynecomastia are possible.

Reduces the effect of levodopa.

Be wary appoint patients with cardiovascular diseases, including with a history of myocardial infarction, stroke, epilepsy, Parkinson's disease. With the development of malignant neuroleptic syndrome (hyperthermia, rigidity of muscles, impaired consciousness), the drug is canceled.

Forms of release: tablets of 0.001; 0.002; 0.003 and 0.004 g (1; 2; 3 and 4 mg) (N. 10, 20, 60); 0.1% solution for oral administration in vials of 30 and 100 ml.

Storage: List B.